Answers are grounded in this paper and cite their sources.
Erratum reports an updated copyright license for the SIERRA study on hepatocellular carcinoma, indicating new terms.
In the article “Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis” [Liver Cancer. 2025; https://doi.org/10.1159/000549955] by Chan et al., the copyright license has been changed to a CC-BY 4.0 license. The original online article has been updated to reflect this.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: